Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2015

View Archived Issues

Gene editing of human intestinal organoids as a model system for colorectal cancer

MRC Technology and NYU School of Medicine to develop antibody for inflammatory osteolysis

GTx licenses University of Tennessee SARD technology

Chugai Pharmaceutical reports on active first quarter of 2015

Novel PDE10 inhibitor demonstrates highly potent and selective tumor cell growth inhibitory activity

Amgen profiles progress of first quarter 2015

Lack of mitochondrial toxicity of AL-335 and AL-516

Positive European opinion on methylnaltrexone bromide for opioid-induced constipation

In vitro test first to detect psychiatric adverse events of drugs

Phase III success with single-dose dalbavancin regimen for Gram-positive skin infections

FDA accepts AbbVie's NDA for all-oral, interferon-free HCV regimen

MedImmune and Juno Therapeutics partner for immuno-oncology clinical trials

CUPID2 trial of Mydicar fails to meet endpoints

First clinical results on antibacterial OP-0595

Mitotech's antioxidant SkQ1 reduces symptoms of dry eye in phase II trial

R-Tech Ueno acquires rights to DE-105 from Santen Pharmaceutical

FDA approves Cyramza for metastatic colorectal cancer

Nissan Chemical patents new Cav3.2 inhibitors

Amgen discloses Nav1.7 inhibitors

Bayer Schering Pharma reports FXIa inhibitors

A*STAR discloses MNK1 and 2 inhibitors

Daewoong reports discovery of H+/K+-ATPase inhibitors

FDA grants orphan drug designation to GW's cannabidiol for neonatal hypoxic-ischemic encephalopathy

EMA committee recommends approval of Opdivo for advanced melanoma

European committee recommends approval of Hetlioz for non-24-hour sleep-wake disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...